nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.117	0.601	CbGbCtD
Epoprostenol—CYP2C9—Progesterone—uterine cancer	0.0777	0.398	CbGbCtD
Epoprostenol—PTGIS—artery—uterine cancer	0.0283	0.137	CbGeAlD
Epoprostenol—P2RY12—artery—uterine cancer	0.0255	0.124	CbGeAlD
Epoprostenol—PTGIR—artery—uterine cancer	0.0163	0.0788	CbGeAlD
Epoprostenol—PTGIS—myometrium—uterine cancer	0.0137	0.0663	CbGeAlD
Epoprostenol—PTGIS—smooth muscle tissue—uterine cancer	0.0104	0.0501	CbGeAlD
Epoprostenol—PTGIS—decidua—uterine cancer	0.0101	0.0492	CbGeAlD
Epoprostenol—P2RY12—epithelium—uterine cancer	0.00967	0.0469	CbGeAlD
Epoprostenol—PTGIS—mammalian vulva—uterine cancer	0.00932	0.0451	CbGeAlD
Epoprostenol—PTGER1—renal system—uterine cancer	0.00926	0.0449	CbGeAlD
Epoprostenol—PTGIS—uterus—uterine cancer	0.00888	0.043	CbGeAlD
Epoprostenol—Bimatoprost—AKR1C3—uterine cancer	0.00877	0.657	CrCbGaD
Epoprostenol—PTGIS—female reproductive system—uterine cancer	0.00798	0.0387	CbGeAlD
Epoprostenol—PTGER1—female reproductive system—uterine cancer	0.00742	0.0359	CbGeAlD
Epoprostenol—PTGIS—female gonad—uterine cancer	0.00726	0.0352	CbGeAlD
Epoprostenol—PTGER1—female gonad—uterine cancer	0.00675	0.0327	CbGeAlD
Epoprostenol—PTGIR—epithelium—uterine cancer	0.00617	0.0299	CbGeAlD
Epoprostenol—PTGIR—smooth muscle tissue—uterine cancer	0.00595	0.0288	CbGeAlD
Epoprostenol—PTGIR—renal system—uterine cancer	0.00572	0.0277	CbGeAlD
Epoprostenol—PTGIS—lymph node—uterine cancer	0.00467	0.0226	CbGeAlD
Epoprostenol—PTGIR—female reproductive system—uterine cancer	0.00458	0.0222	CbGeAlD
Epoprostenol—PTGIR—female gonad—uterine cancer	0.00417	0.0202	CbGeAlD
Epoprostenol—Dinoprostone—CYP11A1—uterine cancer	0.00301	0.226	CrCbGaD
Epoprostenol—PTGIR—lymph node—uterine cancer	0.00268	0.013	CbGeAlD
Epoprostenol—CYP2C9—female reproductive system—uterine cancer	0.00164	0.00793	CbGeAlD
Epoprostenol—Dinoprostone—CYP19A1—uterine cancer	0.00156	0.117	CrCbGaD
Epoprostenol—PTGIS—Adipogenesis—SMAD3—uterine cancer	0.00123	0.0059	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—CYP19A1—uterine cancer	0.0012	0.00576	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.00105	0.00502	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.00105	0.00502	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000771	0.00369	CbGpPWpGaD
Epoprostenol—Pruritus—Progesterone—uterine cancer	0.000678	0.0018	CcSEcCtD
Epoprostenol—Oedema—Dactinomycin—uterine cancer	0.000677	0.0018	CcSEcCtD
Epoprostenol—Infection—Dactinomycin—uterine cancer	0.000673	0.00179	CcSEcCtD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000671	0.00321	CbGpPWpGaD
Epoprostenol—Sepsis—Epirubicin—uterine cancer	0.000668	0.00178	CcSEcCtD
Epoprostenol—Thrombocytopenia—Dactinomycin—uterine cancer	0.000663	0.00176	CcSEcCtD
Epoprostenol—Diarrhoea—Progesterone—uterine cancer	0.000656	0.00174	CcSEcCtD
Epoprostenol—Cramps of lower extremities—Doxorubicin—uterine cancer	0.000655	0.00174	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—NDUFB11—uterine cancer	0.000647	0.00309	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—SRD5A2—uterine cancer	0.000647	0.00309	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—CTNNB1—uterine cancer	0.000646	0.00309	CbGpPWpGaD
Epoprostenol—Anorexia—Dactinomycin—uterine cancer	0.000646	0.00172	CcSEcCtD
Epoprostenol—Flushing—Etoposide—uterine cancer	0.00064	0.0017	CcSEcCtD
Epoprostenol—Cardiac disorder—Etoposide—uterine cancer	0.00064	0.0017	CcSEcCtD
Epoprostenol—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00064	0.0017	CcSEcCtD
Epoprostenol—Pulmonary oedema—Doxorubicin—uterine cancer	0.000634	0.00169	CcSEcCtD
Epoprostenol—Dizziness—Progesterone—uterine cancer	0.000634	0.00168	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000629	0.00301	CbGpPWpGaD
Epoprostenol—Angiopathy—Etoposide—uterine cancer	0.000626	0.00166	CcSEcCtD
Epoprostenol—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000623	0.00166	CcSEcCtD
Epoprostenol—Eczema—Epirubicin—uterine cancer	0.000622	0.00165	CcSEcCtD
Epoprostenol—Hepatic failure—Epirubicin—uterine cancer	0.000622	0.00165	CcSEcCtD
Epoprostenol—Mediastinal disorder—Etoposide—uterine cancer	0.000622	0.00165	CcSEcCtD
Epoprostenol—Chills—Etoposide—uterine cancer	0.000619	0.00165	CcSEcCtD
Epoprostenol—Sepsis—Doxorubicin—uterine cancer	0.000618	0.00164	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000617	0.00164	CcSEcCtD
Epoprostenol—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000614	0.00163	CcSEcCtD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000614	0.00294	CbGpPWpGaD
Epoprostenol—Vomiting—Progesterone—uterine cancer	0.000609	0.00162	CcSEcCtD
Epoprostenol—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000606	0.0029	CbGpPWpGaD
Epoprostenol—Rash—Progesterone—uterine cancer	0.000604	0.00161	CcSEcCtD
Epoprostenol—Dermatitis—Progesterone—uterine cancer	0.000604	0.0016	CcSEcCtD
Epoprostenol—PTGIS—Disease—AKR1B10—uterine cancer	0.000601	0.00287	CbGpPWpGaD
Epoprostenol—Headache—Progesterone—uterine cancer	0.0006	0.0016	CcSEcCtD
Epoprostenol—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000594	0.00158	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000594	0.00284	CbGpPWpGaD
Epoprostenol—Decreased appetite—Dactinomycin—uterine cancer	0.000589	0.00157	CcSEcCtD
Epoprostenol—Fatigue—Dactinomycin—uterine cancer	0.000584	0.00155	CcSEcCtD
Epoprostenol—Back pain—Etoposide—uterine cancer	0.000581	0.00154	CcSEcCtD
Epoprostenol—Pain—Dactinomycin—uterine cancer	0.000579	0.00154	CcSEcCtD
Epoprostenol—Muscle spasms—Etoposide—uterine cancer	0.000577	0.00154	CcSEcCtD
Epoprostenol—Eczema—Doxorubicin—uterine cancer	0.000576	0.00153	CcSEcCtD
Epoprostenol—Hepatic failure—Doxorubicin—uterine cancer	0.000576	0.00153	CcSEcCtD
Epoprostenol—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000574	0.00153	CcSEcCtD
Epoprostenol—Cardiac failure—Epirubicin—uterine cancer	0.000573	0.00152	CcSEcCtD
Epoprostenol—Nausea—Progesterone—uterine cancer	0.000569	0.00151	CcSEcCtD
Epoprostenol—Anaemia—Etoposide—uterine cancer	0.000555	0.00148	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000554	0.00147	CcSEcCtD
Epoprostenol—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000552	0.00147	CcSEcCtD
Epoprostenol—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000548	0.00146	CcSEcCtD
Epoprostenol—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000547	0.00145	CcSEcCtD
Epoprostenol—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000544	0.00145	CcSEcCtD
Epoprostenol—Body temperature increased—Dactinomycin—uterine cancer	0.000535	0.00142	CcSEcCtD
Epoprostenol—Abdominal pain—Dactinomycin—uterine cancer	0.000535	0.00142	CcSEcCtD
Epoprostenol—Cardiac failure—Doxorubicin—uterine cancer	0.00053	0.00141	CcSEcCtD
Epoprostenol—Loss of consciousness—Etoposide—uterine cancer	0.000528	0.0014	CcSEcCtD
Epoprostenol—Cough—Etoposide—uterine cancer	0.000524	0.00139	CcSEcCtD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—AKT1—uterine cancer	0.000521	0.00249	CbGpPWpGaD
Epoprostenol—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000516	0.00137	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—IRF1—uterine cancer	0.000516	0.00247	CbGpPWpGaD
Epoprostenol—Chest pain—Etoposide—uterine cancer	0.000511	0.00136	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Epirubicin—uterine cancer	0.000511	0.00136	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000508	0.00135	CcSEcCtD
Epoprostenol—Hypersensitivity—Dactinomycin—uterine cancer	0.000499	0.00133	CcSEcCtD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000498	0.00238	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—RNF43—uterine cancer	0.000498	0.00238	CbGpPWpGaD
Epoprostenol—Gastritis—Epirubicin—uterine cancer	0.000495	0.00132	CcSEcCtD
Epoprostenol—Confusional state—Etoposide—uterine cancer	0.000494	0.00131	CcSEcCtD
Epoprostenol—Anaphylactic shock—Etoposide—uterine cancer	0.00049	0.0013	CcSEcCtD
Epoprostenol—Infection—Etoposide—uterine cancer	0.000487	0.00129	CcSEcCtD
Epoprostenol—Abdominal distension—Epirubicin—uterine cancer	0.000486	0.00129	CcSEcCtD
Epoprostenol—Asthenia—Dactinomycin—uterine cancer	0.000486	0.00129	CcSEcCtD
Epoprostenol—Thrombocytopenia—Etoposide—uterine cancer	0.00048	0.00128	CcSEcCtD
Epoprostenol—Tachycardia—Etoposide—uterine cancer	0.000478	0.00127	CcSEcCtD
Epoprostenol—Skin disorder—Etoposide—uterine cancer	0.000476	0.00127	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—IRF1—uterine cancer	0.000475	0.00227	CbGpPWpGaD
Epoprostenol—Hyperhidrosis—Etoposide—uterine cancer	0.000474	0.00126	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000472	0.00126	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	0.000469	0.00224	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—STAR—uterine cancer	0.000468	0.00224	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKR1B1—uterine cancer	0.000468	0.00224	CbGpPWpGaD
Epoprostenol—Anorexia—Etoposide—uterine cancer	0.000467	0.00124	CcSEcCtD
Epoprostenol—Diarrhoea—Dactinomycin—uterine cancer	0.000463	0.00123	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000462	0.00221	CbGpPWpGaD
Epoprostenol—Pancytopenia—Epirubicin—uterine cancer	0.000459	0.00122	CcSEcCtD
Epoprostenol—Hypotension—Etoposide—uterine cancer	0.000458	0.00122	CcSEcCtD
Epoprostenol—Gastritis—Doxorubicin—uterine cancer	0.000458	0.00122	CcSEcCtD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000452	0.00216	CbGpPWpGaD
Epoprostenol—Abdominal distension—Doxorubicin—uterine cancer	0.00045	0.0012	CcSEcCtD
Epoprostenol—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000446	0.00213	CbGpPWpGaD
Epoprostenol—Paraesthesia—Etoposide—uterine cancer	0.00044	0.00117	CcSEcCtD
Epoprostenol—Weight decreased—Epirubicin—uterine cancer	0.000437	0.00116	CcSEcCtD
Epoprostenol—Dyspnoea—Etoposide—uterine cancer	0.000437	0.00116	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	0.000436	0.00208	CbGpPWpGaD
Epoprostenol—Somnolence—Etoposide—uterine cancer	0.000436	0.00116	CcSEcCtD
Epoprostenol—Pneumonia—Epirubicin—uterine cancer	0.000433	0.00115	CcSEcCtD
Epoprostenol—Infestation NOS—Epirubicin—uterine cancer	0.000431	0.00115	CcSEcCtD
Epoprostenol—Infestation—Epirubicin—uterine cancer	0.000431	0.00115	CcSEcCtD
Epoprostenol—Vomiting—Dactinomycin—uterine cancer	0.000431	0.00114	CcSEcCtD
Epoprostenol—Rash—Dactinomycin—uterine cancer	0.000427	0.00114	CcSEcCtD
Epoprostenol—Decreased appetite—Etoposide—uterine cancer	0.000426	0.00113	CcSEcCtD
Epoprostenol—Pancytopenia—Doxorubicin—uterine cancer	0.000425	0.00113	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Etoposide—uterine cancer	0.000423	0.00113	CcSEcCtD
Epoprostenol—Fatigue—Etoposide—uterine cancer	0.000423	0.00112	CcSEcCtD
Epoprostenol—Pain—Etoposide—uterine cancer	0.000419	0.00111	CcSEcCtD
Epoprostenol—Constipation—Etoposide—uterine cancer	0.000419	0.00111	CcSEcCtD
Epoprostenol—Urinary tract infection—Epirubicin—uterine cancer	0.000419	0.00111	CcSEcCtD
Epoprostenol—Sweating—Epirubicin—uterine cancer	0.000413	0.0011	CcSEcCtD
Epoprostenol—Haematuria—Epirubicin—uterine cancer	0.000411	0.00109	CcSEcCtD
Epoprostenol—PTGIS—Disease—AKR1C1—uterine cancer	0.00041	0.00196	CbGpPWpGaD
Epoprostenol—Epistaxis—Epirubicin—uterine cancer	0.000406	0.00108	CcSEcCtD
Epoprostenol—Weight decreased—Doxorubicin—uterine cancer	0.000405	0.00108	CcSEcCtD
Epoprostenol—Sinusitis—Epirubicin—uterine cancer	0.000404	0.00107	CcSEcCtD
Epoprostenol—Nausea—Dactinomycin—uterine cancer	0.000402	0.00107	CcSEcCtD
Epoprostenol—Pneumonia—Doxorubicin—uterine cancer	0.000401	0.00107	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Etoposide—uterine cancer	0.000401	0.00107	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—uterine cancer	0.000399	0.00106	CcSEcCtD
Epoprostenol—Infestation—Doxorubicin—uterine cancer	0.000399	0.00106	CcSEcCtD
Epoprostenol—Bradycardia—Epirubicin—uterine cancer	0.000394	0.00105	CcSEcCtD
Epoprostenol—Urticaria—Etoposide—uterine cancer	0.000389	0.00104	CcSEcCtD
Epoprostenol—Haemoglobin—Epirubicin—uterine cancer	0.000389	0.00103	CcSEcCtD
Epoprostenol—Rhinitis—Epirubicin—uterine cancer	0.000388	0.00103	CcSEcCtD
Epoprostenol—Abdominal pain—Etoposide—uterine cancer	0.000388	0.00103	CcSEcCtD
Epoprostenol—Body temperature increased—Etoposide—uterine cancer	0.000388	0.00103	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—uterine cancer	0.000388	0.00103	CcSEcCtD
Epoprostenol—Haemorrhage—Epirubicin—uterine cancer	0.000387	0.00103	CcSEcCtD
Epoprostenol—Hypoaesthesia—Epirubicin—uterine cancer	0.000385	0.00102	CcSEcCtD
Epoprostenol—Pharyngitis—Epirubicin—uterine cancer	0.000384	0.00102	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—uterine cancer	0.000382	0.00102	CcSEcCtD
Epoprostenol—Oedema peripheral—Epirubicin—uterine cancer	0.000381	0.00101	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—uterine cancer	0.00038	0.00101	CcSEcCtD
Epoprostenol—Connective tissue disorder—Epirubicin—uterine cancer	0.00038	0.00101	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—uterine cancer	0.000376	0.001	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—uterine cancer	0.000374	0.000994	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—POLD1—uterine cancer	0.000367	0.00176	CbGpPWpGaD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000366	0.00175	CbGpPWpGaD
Epoprostenol—Bradycardia—Doxorubicin—uterine cancer	0.000364	0.000969	CcSEcCtD
Epoprostenol—Hypersensitivity—Etoposide—uterine cancer	0.000361	0.00096	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—uterine cancer	0.00036	0.000956	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—uterine cancer	0.000359	0.000954	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—uterine cancer	0.000359	0.000954	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—uterine cancer	0.000359	0.000954	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—uterine cancer	0.000358	0.000951	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—uterine cancer	0.000356	0.000947	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—uterine cancer	0.000355	0.000944	CcSEcCtD
Epoprostenol—PTGIS—Disease—DCN—uterine cancer	0.000355	0.0017	CbGpPWpGaD
Epoprostenol—Oedema peripheral—Doxorubicin—uterine cancer	0.000353	0.000937	CcSEcCtD
Epoprostenol—Asthenia—Etoposide—uterine cancer	0.000352	0.000935	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—uterine cancer	0.000352	0.000935	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—uterine cancer	0.000351	0.000933	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000349	0.00167	CbGpPWpGaD
Epoprostenol—Mediastinal disorder—Epirubicin—uterine cancer	0.000349	0.000927	CcSEcCtD
Epoprostenol—Chills—Epirubicin—uterine cancer	0.000347	0.000923	CcSEcCtD
Epoprostenol—P2RY12—G alpha (i) signalling events—CXCL8—uterine cancer	0.000347	0.00166	CbGpPWpGaD
Epoprostenol—Pruritus—Etoposide—uterine cancer	0.000347	0.000922	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—AKR1C1—uterine cancer	0.000343	0.00164	CbGpPWpGaD
Epoprostenol—Mental disorder—Epirubicin—uterine cancer	0.000339	0.000901	CcSEcCtD
Epoprostenol—Diarrhoea—Etoposide—uterine cancer	0.000335	0.000892	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—AKR1B10—uterine cancer	0.000335	0.0016	CbGpPWpGaD
Epoprostenol—Flushing—Doxorubicin—uterine cancer	0.000332	0.000883	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—uterine cancer	0.000332	0.000883	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—uterine cancer	0.000332	0.000882	CcSEcCtD
Epoprostenol—Tension—Epirubicin—uterine cancer	0.00033	0.000878	CcSEcCtD
Epoprostenol—Nervousness—Epirubicin—uterine cancer	0.000327	0.000869	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—uterine cancer	0.000326	0.000866	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—uterine cancer	0.000325	0.000863	CcSEcCtD
Epoprostenol—Dizziness—Etoposide—uterine cancer	0.000324	0.000862	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—uterine cancer	0.000324	0.000861	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—uterine cancer	0.000323	0.000858	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—uterine cancer	0.000321	0.000854	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000321	0.00153	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000321	0.00153	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	0.00032	0.00153	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKR1C3—uterine cancer	0.000316	0.00151	CbGpPWpGaD
Epoprostenol—Mental disorder—Doxorubicin—uterine cancer	0.000314	0.000834	CcSEcCtD
Epoprostenol—Vomiting—Etoposide—uterine cancer	0.000312	0.000829	CcSEcCtD
Epoprostenol—Anaemia—Epirubicin—uterine cancer	0.000311	0.000827	CcSEcCtD
Epoprostenol—Agitation—Epirubicin—uterine cancer	0.000309	0.000823	CcSEcCtD
Epoprostenol—Rash—Etoposide—uterine cancer	0.000309	0.000822	CcSEcCtD
Epoprostenol—Dermatitis—Etoposide—uterine cancer	0.000309	0.000821	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—AKR1B10—uterine cancer	0.000308	0.00147	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKR1B10—uterine cancer	0.000308	0.00147	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HMGA1—uterine cancer	0.000308	0.00147	CbGpPWpGaD
Epoprostenol—Headache—Etoposide—uterine cancer	0.000307	0.000816	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—uterine cancer	0.000307	0.000816	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—RRM2—uterine cancer	0.000306	0.00146	CbGpPWpGaD
Epoprostenol—Tension—Doxorubicin—uterine cancer	0.000306	0.000813	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—uterine cancer	0.000303	0.000804	CcSEcCtD
Epoprostenol—Syncope—Epirubicin—uterine cancer	0.000302	0.000803	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—uterine cancer	0.000301	0.000801	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—uterine cancer	0.0003	0.000796	CcSEcCtD
Epoprostenol—Palpitations—Epirubicin—uterine cancer	0.000298	0.000791	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—DCN—uterine cancer	0.000297	0.00142	CbGpPWpGaD
Epoprostenol—Loss of consciousness—Epirubicin—uterine cancer	0.000296	0.000787	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	0.000296	0.00141	CbGpPWpGaD
Epoprostenol—Cough—Epirubicin—uterine cancer	0.000294	0.000781	CcSEcCtD
Epoprostenol—Nausea—Etoposide—uterine cancer	0.000291	0.000774	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—uterine cancer	0.000288	0.000766	CcSEcCtD
Epoprostenol—Chest pain—Epirubicin—uterine cancer	0.000287	0.000762	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—uterine cancer	0.000287	0.000762	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—uterine cancer	0.000287	0.000762	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—uterine cancer	0.000286	0.000761	CcSEcCtD
Epoprostenol—Anxiety—Epirubicin—uterine cancer	0.000286	0.000759	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000285	0.000757	CcSEcCtD
Epoprostenol—PTGIS—Disease—FBXW7—uterine cancer	0.000281	0.00135	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	0.000281	0.00134	CbGpPWpGaD
Epoprostenol—Dry mouth—Epirubicin—uterine cancer	0.00028	0.000745	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CYP11A1—uterine cancer	0.00028	0.00134	CbGpPWpGaD
Epoprostenol—Syncope—Doxorubicin—uterine cancer	0.000279	0.000743	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—RNF43—uterine cancer	0.000277	0.00133	CbGpPWpGaD
Epoprostenol—Confusional state—Epirubicin—uterine cancer	0.000277	0.000737	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000276	0.00132	CbGpPWpGaD
Epoprostenol—Palpitations—Doxorubicin—uterine cancer	0.000275	0.000732	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	0.000275	0.00131	CbGpPWpGaD
Epoprostenol—Anaphylactic shock—Epirubicin—uterine cancer	0.000275	0.000731	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—uterine cancer	0.000275	0.000731	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—uterine cancer	0.000274	0.000728	CcSEcCtD
Epoprostenol—Infection—Epirubicin—uterine cancer	0.000273	0.000726	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—uterine cancer	0.000272	0.000723	CcSEcCtD
Epoprostenol—Shock—Epirubicin—uterine cancer	0.00027	0.000719	CcSEcCtD
Epoprostenol—Nervous system disorder—Epirubicin—uterine cancer	0.000269	0.000716	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—uterine cancer	0.000269	0.000715	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—uterine cancer	0.000268	0.000713	CcSEcCtD
Epoprostenol—Skin disorder—Epirubicin—uterine cancer	0.000267	0.00071	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—uterine cancer	0.000266	0.000706	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—CCL2—uterine cancer	0.000266	0.00127	CbGpPWpGaD
Epoprostenol—Chest pain—Doxorubicin—uterine cancer	0.000265	0.000705	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—uterine cancer	0.000265	0.000705	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—uterine cancer	0.000265	0.000705	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	0.000264	0.00126	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKR1C3—uterine cancer	0.000264	0.00126	CbGpPWpGaD
Epoprostenol—Anxiety—Doxorubicin—uterine cancer	0.000264	0.000703	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000263	0.0007	CcSEcCtD
Epoprostenol—Anorexia—Epirubicin—uterine cancer	0.000262	0.000696	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	0.000261	0.00125	CbGpPWpGaD
Epoprostenol—Dry mouth—Doxorubicin—uterine cancer	0.000259	0.00069	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—uterine cancer	0.000257	0.000683	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—uterine cancer	0.000256	0.000682	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—RNF43—uterine cancer	0.000255	0.00122	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RNF43—uterine cancer	0.000255	0.00122	CbGpPWpGaD
Epoprostenol—Anaphylactic shock—Doxorubicin—uterine cancer	0.000254	0.000676	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—uterine cancer	0.000254	0.000676	CcSEcCtD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000254	0.00121	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000254	0.00121	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—INHBA—uterine cancer	0.000254	0.00121	CbGpPWpGaD
Epoprostenol—Infection—Doxorubicin—uterine cancer	0.000253	0.000672	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.00025	0.000666	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—uterine cancer	0.00025	0.000665	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—uterine cancer	0.000249	0.000663	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—uterine cancer	0.000249	0.000662	CcSEcCtD
Epoprostenol—Insomnia—Epirubicin—uterine cancer	0.000249	0.000661	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—uterine cancer	0.000248	0.00066	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—uterine cancer	0.000247	0.000657	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—uterine cancer	0.000247	0.000656	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	0.000246	0.00118	CbGpPWpGaD
Epoprostenol—Hyperhidrosis—Doxorubicin—uterine cancer	0.000246	0.000653	CcSEcCtD
Epoprostenol—Dyspnoea—Epirubicin—uterine cancer	0.000245	0.000651	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—CCL2—uterine cancer	0.000244	0.00117	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCL2—uterine cancer	0.000244	0.00117	CbGpPWpGaD
Epoprostenol—Somnolence—Epirubicin—uterine cancer	0.000244	0.000649	CcSEcCtD
Epoprostenol—PTGER1—G alpha (q) signalling events—PIK3CA—uterine cancer	0.000243	0.00116	CbGpPWpGaD
Epoprostenol—Anorexia—Doxorubicin—uterine cancer	0.000242	0.000644	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—uterine cancer	0.000242	0.000643	CcSEcCtD
Epoprostenol—Decreased appetite—Epirubicin—uterine cancer	0.000239	0.000635	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—uterine cancer	0.000238	0.000632	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000237	0.000631	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—uterine cancer	0.000237	0.00063	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	0.000237	0.00113	CbGpPWpGaD
Epoprostenol—Pain—Epirubicin—uterine cancer	0.000235	0.000625	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—uterine cancer	0.000235	0.000625	CcSEcCtD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000235	0.00112	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—INHBA—uterine cancer	0.000233	0.00112	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—INHBA—uterine cancer	0.000233	0.00112	CbGpPWpGaD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000232	0.000616	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	0.000231	0.00111	CbGpPWpGaD
Epoprostenol—Insomnia—Doxorubicin—uterine cancer	0.00023	0.000611	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—AKR1C1—uterine cancer	0.000228	0.00109	CbGpPWpGaD
Epoprostenol—Paraesthesia—Doxorubicin—uterine cancer	0.000228	0.000607	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—uterine cancer	0.000227	0.000603	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—uterine cancer	0.000226	0.000601	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Epirubicin—uterine cancer	0.000225	0.000597	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—uterine cancer	0.000224	0.000595	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—uterine cancer	0.000221	0.000588	CcSEcCtD
Epoprostenol—PTGIS—Disease—CDKN2B—uterine cancer	0.00022	0.00105	CbGpPWpGaD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.00022	0.000584	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—uterine cancer	0.000219	0.000583	CcSEcCtD
Epoprostenol—Urticaria—Epirubicin—uterine cancer	0.000218	0.00058	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	0.000217	0.00104	CbGpPWpGaD
Epoprostenol—Pain—Doxorubicin—uterine cancer	0.000217	0.000578	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—uterine cancer	0.000217	0.000578	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—uterine cancer	0.000217	0.000578	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—uterine cancer	0.000217	0.000578	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—AKR1C1—uterine cancer	0.00021	0.001	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKR1C1—uterine cancer	0.00021	0.001	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CXCL8—uterine cancer	0.00021	0.001	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000208	0.000553	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CYP19A1—uterine cancer	0.000206	0.000985	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—STK11—uterine cancer	0.000206	0.000985	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Epirubicin—uterine cancer	0.000202	0.000538	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—uterine cancer	0.000202	0.000537	CcSEcCtD
Epoprostenol—PTGIS—Disease—SMAD3—uterine cancer	0.000201	0.000962	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	0.000201	0.000962	CbGpPWpGaD
Epoprostenol—Abdominal pain—Doxorubicin—uterine cancer	0.000201	0.000534	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—uterine cancer	0.000201	0.000534	CcSEcCtD
Epoprostenol—Asthenia—Epirubicin—uterine cancer	0.000197	0.000524	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	0.000195	0.00093	CbGpPWpGaD
Epoprostenol—Pruritus—Epirubicin—uterine cancer	0.000194	0.000517	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	0.000193	0.000924	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CXCL8—uterine cancer	0.000193	0.000924	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CXCL8—uterine cancer	0.000193	0.000924	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—FGFR2—uterine cancer	0.000192	0.000918	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	0.000192	0.000918	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—AKT1—uterine cancer	0.000189	0.000903	CbGpPWpGaD
Epoprostenol—Diarrhoea—Epirubicin—uterine cancer	0.000188	0.0005	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—uterine cancer	0.000187	0.000498	CcSEcCtD
Epoprostenol—PTGIS—Disease—MTHFR—uterine cancer	0.000185	0.000884	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—EP300—uterine cancer	0.000184	0.000881	CbGpPWpGaD
Epoprostenol—Asthenia—Doxorubicin—uterine cancer	0.000182	0.000485	CcSEcCtD
Epoprostenol—Dizziness—Epirubicin—uterine cancer	0.000182	0.000483	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—uterine cancer	0.00018	0.000478	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—AKR1C3—uterine cancer	0.000176	0.000841	CbGpPWpGaD
Epoprostenol—Vomiting—Epirubicin—uterine cancer	0.000175	0.000465	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—uterine cancer	0.000174	0.000463	CcSEcCtD
Epoprostenol—Rash—Epirubicin—uterine cancer	0.000173	0.000461	CcSEcCtD
Epoprostenol—Dermatitis—Epirubicin—uterine cancer	0.000173	0.00046	CcSEcCtD
Epoprostenol—Headache—Epirubicin—uterine cancer	0.000172	0.000458	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—PGR—uterine cancer	0.000171	0.000819	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.00017	0.000812	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.00017	0.000812	CbGpPWpGaD
Epoprostenol—Dizziness—Doxorubicin—uterine cancer	0.000168	0.000447	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—YWHAE—uterine cancer	0.000163	0.000781	CbGpPWpGaD
Epoprostenol—Nausea—Epirubicin—uterine cancer	0.000163	0.000434	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—AKR1C3—uterine cancer	0.000162	0.000774	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKR1C3—uterine cancer	0.000162	0.000774	CbGpPWpGaD
Epoprostenol—Vomiting—Doxorubicin—uterine cancer	0.000162	0.00043	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—EP300—uterine cancer	0.000161	0.00077	CbGpPWpGaD
Epoprostenol—Rash—Doxorubicin—uterine cancer	0.00016	0.000426	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—uterine cancer	0.00016	0.000426	CcSEcCtD
Epoprostenol—Headache—Doxorubicin—uterine cancer	0.000159	0.000423	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—PGR—uterine cancer	0.000158	0.000754	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PGR—uterine cancer	0.000158	0.000754	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FBXW7—uterine cancer	0.000157	0.000749	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—MTHFR—uterine cancer	0.000155	0.00074	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—uterine cancer	0.000153	0.000729	CbGpPWpGaD
Epoprostenol—Nausea—Doxorubicin—uterine cancer	0.000151	0.000402	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—NRAS—uterine cancer	0.000151	0.00072	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—YWHAE—uterine cancer	0.00015	0.000719	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—YWHAE—uterine cancer	0.00015	0.000719	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—EP300—uterine cancer	0.000148	0.000709	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FBXW7—uterine cancer	0.000144	0.000689	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FBXW7—uterine cancer	0.000144	0.000689	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—uterine cancer	0.00014	0.000671	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—NRAS—uterine cancer	0.000139	0.000663	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STK11—uterine cancer	0.000137	0.000655	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	0.000136	0.000652	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CCL2—uterine cancer	0.000136	0.000652	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—KRAS—uterine cancer	0.00013	0.00062	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SOCS3—uterine cancer	0.000128	0.000613	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STK11—uterine cancer	0.000126	0.000603	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STK11—uterine cancer	0.000126	0.000603	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCL2—uterine cancer	0.000125	0.0006	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCL2—uterine cancer	0.000125	0.0006	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000125	0.000596	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN2B—uterine cancer	0.000123	0.000587	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ERBB2—uterine cancer	0.000121	0.000576	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—KRAS—uterine cancer	0.000119	0.000571	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1R—uterine cancer	0.000119	0.00057	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—PIK3CA—uterine cancer	0.000119	0.00057	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCL8—uterine cancer	0.000119	0.000567	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SOCS3—uterine cancer	0.000118	0.000564	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SOCS3—uterine cancer	0.000118	0.000564	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—uterine cancer	0.000115	0.000551	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN2B—uterine cancer	0.000113	0.00054	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN2B—uterine cancer	0.000113	0.00054	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SMAD3—uterine cancer	0.000112	0.000536	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN1B—uterine cancer	0.000112	0.000534	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—HRAS—uterine cancer	0.00011	0.000527	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1R—uterine cancer	0.00011	0.000525	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1R—uterine cancer	0.00011	0.000525	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PIK3CA—uterine cancer	0.00011	0.000524	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL8—uterine cancer	0.000109	0.000522	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL8—uterine cancer	0.000109	0.000522	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL8—uterine cancer	0.000108	0.000515	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGFR2—uterine cancer	0.000107	0.000511	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—uterine cancer	0.000106	0.000507	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CTNNB1—uterine cancer	0.000105	0.000504	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NDUFB11—uterine cancer	0.000105	0.0005	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SRD5A2—uterine cancer	0.000105	0.0005	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SMAD3—uterine cancer	0.000103	0.000493	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SMAD3—uterine cancer	0.000103	0.000493	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTEN—uterine cancer	0.000103	0.000492	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000102	0.000486	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—uterine cancer	0.000101	0.000485	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—uterine cancer	9.92e-05	0.000474	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—uterine cancer	9.92e-05	0.000474	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGFR2—uterine cancer	9.84e-05	0.00047	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGFR2—uterine cancer	9.84e-05	0.00047	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EP300—uterine cancer	9.8e-05	0.000469	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—uterine cancer	9.73e-05	0.000465	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	9.59e-05	0.000459	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NRAS—uterine cancer	9.17e-05	0.000439	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ESR1—uterine cancer	9.15e-05	0.000437	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—uterine cancer	8.96e-05	0.000428	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—NRAS—uterine cancer	8.65e-05	0.000413	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTEN—uterine cancer	8.61e-05	0.000412	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ESR1—uterine cancer	8.42e-05	0.000402	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ESR1—uterine cancer	8.42e-05	0.000402	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—EP300—uterine cancer	8.21e-05	0.000393	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCL2—uterine cancer	8.05e-05	0.000385	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—NRAS—uterine cancer	7.96e-05	0.00038	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—NRAS—uterine cancer	7.96e-05	0.00038	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—uterine cancer	7.89e-05	0.000377	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKR1B1—uterine cancer	7.56e-05	0.000361	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—STAR—uterine cancer	7.56e-05	0.000361	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—uterine cancer	7.53e-05	0.00036	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.47e-05	0.000357	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—uterine cancer	7.44e-05	0.000356	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL2—uterine cancer	7.41e-05	0.000354	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL2—uterine cancer	7.41e-05	0.000354	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—uterine cancer	7.25e-05	0.000347	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—uterine cancer	6.93e-05	0.000331	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—uterine cancer	6.93e-05	0.000331	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—uterine cancer	6.85e-05	0.000327	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—uterine cancer	6.85e-05	0.000327	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—uterine cancer	6.84e-05	0.000327	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB2—uterine cancer	6.71e-05	0.000321	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—uterine cancer	6.71e-05	0.000321	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—uterine cancer	6.37e-05	0.000304	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—uterine cancer	6.33e-05	0.000302	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—uterine cancer	6.29e-05	0.000301	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—uterine cancer	6.29e-05	0.000301	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1B—uterine cancer	6.22e-05	0.000297	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB2—uterine cancer	6.18e-05	0.000295	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB2—uterine cancer	6.18e-05	0.000295	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—uterine cancer	6.15e-05	0.000294	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—uterine cancer	6.07e-05	0.00029	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—POLD1—uterine cancer	5.93e-05	0.000284	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—uterine cancer	5.92e-05	0.000283	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNB1—uterine cancer	5.87e-05	0.000281	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—uterine cancer	5.86e-05	0.00028	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—uterine cancer	5.86e-05	0.00028	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—uterine cancer	5.82e-05	0.000278	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—uterine cancer	5.82e-05	0.000278	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—uterine cancer	5.73e-05	0.000274	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1B—uterine cancer	5.72e-05	0.000274	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1B—uterine cancer	5.72e-05	0.000274	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—uterine cancer	5.66e-05	0.000271	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—uterine cancer	5.66e-05	0.000271	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—uterine cancer	5.59e-05	0.000267	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKR1C1—uterine cancer	5.55e-05	0.000265	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EP300—uterine cancer	5.46e-05	0.000261	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNB1—uterine cancer	5.41e-05	0.000258	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNB1—uterine cancer	5.41e-05	0.000258	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—uterine cancer	5.27e-05	0.000252	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—uterine cancer	5.27e-05	0.000252	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—uterine cancer	5.17e-05	0.000247	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—uterine cancer	5.14e-05	0.000246	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—uterine cancer	5.14e-05	0.000246	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NRAS—uterine cancer	5.11e-05	0.000244	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EP300—uterine cancer	5.02e-05	0.00024	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EP300—uterine cancer	5.02e-05	0.00024	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—uterine cancer	4.96e-05	0.000237	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—RRM2—uterine cancer	4.95e-05	0.000236	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—DCN—uterine cancer	4.8e-05	0.00023	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—uterine cancer	4.76e-05	0.000228	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—uterine cancer	4.76e-05	0.000228	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NRAS—uterine cancer	4.7e-05	0.000225	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NRAS—uterine cancer	4.7e-05	0.000225	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP11A1—uterine cancer	4.52e-05	0.000216	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—uterine cancer	4.4e-05	0.00021	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKR1C3—uterine cancer	4.27e-05	0.000204	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—uterine cancer	4.05e-05	0.000193	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—uterine cancer	4.05e-05	0.000193	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—uterine cancer	4.04e-05	0.000193	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—uterine cancer	3.91e-05	0.000187	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—uterine cancer	3.74e-05	0.000179	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—uterine cancer	3.72e-05	0.000178	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—uterine cancer	3.72e-05	0.000178	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—uterine cancer	3.6e-05	0.000172	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—uterine cancer	3.6e-05	0.000172	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—uterine cancer	3.44e-05	0.000164	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—uterine cancer	3.44e-05	0.000164	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—STK11—uterine cancer	3.33e-05	0.000159	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP19A1—uterine cancer	3.33e-05	0.000159	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—uterine cancer	3.3e-05	0.000158	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.12e-05	0.000149	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—uterine cancer	3.04e-05	0.000145	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—uterine cancer	3.04e-05	0.000145	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.98e-05	0.000142	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—uterine cancer	2.5e-05	0.00012	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.2e-05	0.000105	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—uterine cancer	1.39e-05	6.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—EP300—uterine cancer	1.33e-05	6.34e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—uterine cancer	9.81e-06	4.69e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—uterine cancer	8.02e-06	3.83e-05	CbGpPWpGaD
